

Anti-TIGIT Antibody (Tiragolumab)

Introduction

Tiragolumab is an immune checkpoint inhibitor that binds to the T cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab alone or in combination with the PD-L1 inhibitor atezolizumab may be effective against a variety of solid malignancies, especially non-small cell lung cancer (NSCLC).

Product parameters

Alternative Names	RG6058, MTIG7192A, RO7092284
Target Accession	Q495A1
Target	TIGIT
CAS number	1918185-84-8
Molecular Weight	148.66 kDa
Host	CHO
Reactivity	Human, Mouse, Cynomolgus
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human TIGIT His at 2 ug/mL can bind Anti-TIGIT Antibody (Tiragolumab), EC50=0.01643 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

